Skip to main content
. 2010 Nov 29;29(1):32–39. doi: 10.1200/JCO.2009.26.4473

Table 4.

Analysis Restricted to Women With Blood Glucose Level < 126 mg/dL (n = 451)

Variable No. of Events/ No. of Patients Unadjusted
 Model 1*
 Model 2†
HR 95% CI P‡ HR 95% CI P‡ HR 95% CI P‡
Breast cancer mortality
    Adiponectin, μg/mL .02 .01 .003
        0.85-15.50 16/212 1.00 Ref 1.00 Ref 1.00 Ref
        15.50-74.45 6/239 0.33 0.13 to 0.83 0.26 0.10 to 0.73 0.21 0.07 to 0.46
    Adiponectin, μg/mL N/S N/S N/S
        0.85-74.45 22/451 0.99 0.99 to 1.00 0.99 0.99 to 1.00 0.99 0.99 to 1.00
    HOMA N/S N/S N/S
        0.26-1.22 7/172 1.00 Ref. 1.00 Ref. 1.00 Ref.
        1.23-2.26 10/163 1.51 0.57 to 3.97 1.89 0.68 to 5.26 2.40 0.84 to 6.83
        2.27-23.91 5/116 1.06 0.33 to 3.35 1.32 0.23 to 5.71 1.12 0.31 to 6.42
    HOMA N/S N/S N/S
        0.25-23.91 22/451 1.05 0.89 to 1.23 1.04 0.86 to 1.24 1.05 0.87 to 1.27
All-cause mortality
    Adiponectin, μg/mL N/S .046 .02
        0.85-15.50 29/212 1.00 Ref 1.00 Ref. 1.00 Ref.
        15.50-74.45 25/239 0.75 0.44 to 1.29 0.56 0.31 to 0.99 0.51 0.28 to 0.91
    Adiponectin, μg/mL N/S N/S N/S
        0.85-74.45 54/451 1.00 0.99 to 1.01 1.00 0.99 to 1.01 1.00 0.99 to 1.01
    HOMA N/S N/S N/S
        0.26-1.22 21/172 1.00 Ref. 1.00 Ref. 1.00 Ref.
        1.23-2.26 19/163 0.98 0.53 to 1.83 0.92 0.48 to 1.79 1.01 0.51 to 1.96
        2.27-23.91 14/116 1.01 0.52 to 1.99 0.88 0.37 to 2.06 0.96 0.40 to 2.30
    HOMA N/S N/S N/S
        0.25-23.91 54/451 1.04 0.92 to 1.16 1.04 0.91 to 1.18 1.06 0.92 to 1.21

NOTE. As described in Methods, we used a stricter criterion to assess statistical significance in subgroup analyses (P < .006).

Abbreviations: HR, hazard ratio; Ref., reference; N/S, not significant; HOMA, Homeostatic Model Assessment.

*

Adjusted for age (continuous), body mass index (categorical < 18.5, ≥ 18.5 and < 25, ≥ 25 and < 40, > 40 kg/m2), ethnicity/site, and tamoxifen use at time of blood draw (yes/no).

†

Adjusted for age (continuous); body mass index (categorical < 18.5, ≥ 18.5 and < 25, ≥ 25 and < 40, > 40 kg/m2), ethnicity/site, tamoxifen use at time of blood draw (yes/no), estradiol levels (continuous), leptin levels (continuous), and insulin-like growth factor 1 levels (continuous).

‡

Wald test for trend.